These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8076440)

  • 1. Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis.
    Joffe P; Cintin C; Ladefoged SD; Rasmussen SN
    Clin Nephrol; 1994 Jun; 41(6):364-9. PubMed ID: 8076440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effect of oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol on markers of bone metabolism.
    Joffe P; Ladefoged SD; Cintin C; Jensen LT; Hyldstrup L
    Nephrol Dial Transplant; 1994; 9(5):524-31. PubMed ID: 8090332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis.
    Jones CL; Vieth R; Spino M; Ledermann S; Kooh SW; Balfe J; Balfe JW
    Clin Nephrol; 1994 Jul; 42(1):44-9. PubMed ID: 7923966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis.
    Kimura Y; Nakayama M; Kuriyama S; Watanabe S; Kawaguchi Y; Sakai O
    Clin Nephrol; 1991 Feb; 35(2):72-7. PubMed ID: 2019017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis.
    Papapoulos SE; vd Berg H; Frölich M; Valentijn RM
    Nephrol Dial Transplant; 1988; 3(5):647-50. PubMed ID: 3146722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients.
    Salusky IB; Goodman WG; Horst R; Segre GV; Kim L; Norris KC; Adams JS; Holloway M; Fine RN; Coburn JW
    Am J Kidney Dis; 1990 Aug; 16(2):126-32. PubMed ID: 2382648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacokinetics of 1 alpha-hydroxyvitamin D3 tritiated at 22 and 23 positions showing high specific radioactivity.
    Kawase A; Ichikawa F; Koike N; Kamachi S; Stumpf WE; Nishii Y; Kubodera N
    Chem Pharm Bull (Tokyo); 2000 Feb; 48(2):215-9. PubMed ID: 10705507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1 alpha-Hydroxycholecalciferol adsorption to peritoneal dialysis bags: influence of time, glucose concentration, temperature, and albumin.
    Joffe P; Ladefoged SD; Cintin C; Lehmann H
    Nephrol Dial Transplant; 1992; 7(12):1249-51. PubMed ID: 1337168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
    Brandi L; Egfjord M; Olgaard K
    Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
    Djukanović L; Pejanović S; Dragojlović Z; Stosović M
    Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Ateshkadi A; Johnson CA; Oxton LL; Hammond TG; Bohenek WS; Zimmerman SW
    Am J Kidney Dis; 1993 Jun; 21(6):635-42. PubMed ID: 8503418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis.
    Bouchet JL; Albin H; Quentin C; de Barbeyrac B; Vinçon G; Martin-Dupont P; Potaux L; Aparicio M
    Clin Nephrol; 1988 Jan; 29(1):35-40. PubMed ID: 3383462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men.
    Brandi L; Egfjord M; Olgaard K
    Nephrol Dial Transplant; 2002 May; 17(5):829-42. PubMed ID: 11981071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dietary vitamin D3 on the circulating concentration of its active metabolites in the chick and rat.
    Hughes MR; Baylink DJ; Gonnerman WA; Toverud SU; Ramp WK; Haussler MR
    Endocrinology; 1977 Mar; 100(3):799-806. PubMed ID: 233823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
    Zuo Z; Tam YK; Diakur J; Wiebe LI
    J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating 1 alpha,25-dihydroxyvitamin D levels after a single dose of 1 alpha,25-dihydroxyvitamin D3 or 1 alpha-hydroxyvitamin D3 in normal men.
    Seino Y; Tanaka H; Yamaoka K; Yabuuchi H
    Bone Miner; 1987 Sep; 2(6):479-85. PubMed ID: 3505770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of parenteral administration of 25-hydroxycholecalciferol and 1 alpha-hydroxycholecalciferol on the mineral concentrations in the blood of cows in late pregnancy].
    Zepperitz H; Schwabe H
    Berl Munch Tierarztl Wochenschr; 1993 Jun; 106(6):183-8. PubMed ID: 8343104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.